Quaratusugene ozeplasmid is under clinical development by Genprex and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Quaratusugene ozeplasmid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Quaratusugene ozeplasmid overview
GPX-001 in combination with erlotinib, osimertinib and pembrolizumab is under development for the treatment of KRAS/STK11 mutated non-small cell lung cancer, small-cell lung cancer and glioblastoma multiforme (GBM). The drug candidate comprises of cancer-fighting genes which is encapsulated into nanoscale hollow spheres called nanovesicles and administered through intravenous route. It acts by targeting TUSC2 protein and Nitrogen Permease Regulator 2 Like Protein. The drug candidate is being developed based on oncoprex nanovesicle delivery system technology.
The drug candidate was also under development for the treatment of small cell lung cancer, metastatic lung cancer, other solid tumors include head and neck, TNBC, kidney and soft tissue cancer.
Genprex overview
Genprex is a clinical-stage gene therapy company that develops gene-based therapies for cancer. The company pipeline lead pipeline products include REQORSA for the treatment of non-small cell lung cancer and small cell lung cancer. Its other pipelines include GPX-002 and GPX-003 for treatment of type 1 and type 2 diabetes. Genprex also utilizes Oncoprex, a non-viral nanoparticle delivery system. The company works with institutions and collaborators to develop drug candidates to further the pipeline of gene therapies for novel treatment. Genprex is headquartered in Austin, Texas, the US.
For a complete picture of Quaratusugene ozeplasmid’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
